Document is current
Any future updates will be listed below
-
Authors
Stanton, Sasha E https://orcid.org/0000-0002-4300-551X
Anderson, Kristin G
Bruno, Tullia C
Capitini, Christian M https://orcid.org/0000-0002-2276-6731
Disis, Mary L
McQuade, Jennifer
Radvanyi, Laszlo
Vanpouille-Box, Claire https://orcid.org/0000-0001-7213-0670
Wargo, Jennifer
Baines, Kelly J
Hong, Megan M Y
Rajeh, Adnan
Kim, Raymond H
Awadalla, Phillip
Hughes, Lauren K
Maleki Vareki, Saman
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct00128661 at ClinicalTrials.govnct04367675 at ClinicalTrials.govDocuments that mention this clinical trial
ESGO Prevention Committee opinion: is a single dose of HPV vaccine good enough?
https://doi.org/10.1136/ijgc-2023-004295
The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias
https://doi.org/10.1136/bmjebm-2018-111012
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419
Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial
https://doi.org/10.1136/sextrans-2022-055434
nct05078866 at ClinicalTrials.govDocuments that mention this clinical trial
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419
Phase 1 study of safety, tolerability and immunogenicity of the human telomerase (hTERT)-encoded DNA plasmids INO-1400 and INO-1401 with or without IL-12 DNA plasmid INO-9012 in adult patients with solid tumors
https://doi.org/10.1136/jitc-2021-003019
Shared epitopes create safety and efficacy concerns in several cancer vaccines
https://doi.org/10.1136/jitc-2025-012217
Advances and challenges in cancer immunoprevention and immune interception
https://doi.org/10.1136/jitc-2023-007815
isrctn59521990 at ISRCTN.orgDocuments that mention this clinical trial
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419
1336 Final Ph1b/2 results for nous-209 monotherapy in lynch syndrome carriers: annual revaccination boosts T cell immunity informing future cancer interception strategies
https://doi.org/10.1136/jitc-2025-sitc2025.1336
Discovery and validation of frameshift-derived neopeptides in Lynch syndrome: paving the way for novel cancer prevention strategies
https://doi.org/10.1136/jitc-2024-011177
Advances and challenges in cancer immunoprevention and immune interception
https://doi.org/10.1136/jitc-2023-007815
nct02780401 at ClinicalTrials.govDocuments that mention this clinical trial
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial
https://doi.org/10.1016/s0140-6736(11)61049-0
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419
Documents that mention this clinical trial
SITC strategic vision: prevention, premalignant immunity, host and environmental factors
https://doi.org/10.1136/jitc-2024-010419
- License Information
